<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01671332</url>
  </required_header>
  <id_info>
    <org_study_id>CO11508</org_study_id>
    <nct_id>NCT01671332</nct_id>
  </id_info>
  <brief_title>Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Randomized Phase II Study of Suramin and Docetaxel Versus Docetaxel in Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Optimum Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of the study is to determine whether or not the inclusion of suramin to
      standard treatment with docetaxel improves progression-free survival for patients with
      advanced non-small cell lung cancer in the second and third line settings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall purpose of the study is to determine whether or not the inclusion of suramin to
      standard treatment with docetaxel improves progression-free survival for patients with
      advanced non-small cell lung cancer in the second and third line settings.

      Secondary objectives include:

        -  To compare response rate of patients in both treatment arms

        -  To compare overall survival of patients in both treatment arms

        -  To compare toxicity in both treatment arms

        -  To determine whether the survival benefit from suramin is associated with reduced
           M-phase entry in peripheral blood lymphocytes
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival in months</measure>
    <time_frame>From the time of randomization to the time of progression of disease, evaluated every 6 weeks, for up to 52 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate per RECIST 1.1 criteria</measure>
    <time_frame>From baseline to the time of response, evaluated every 6 weeks, for up to 52 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the time of registration to the time of death, assessed once each month for up to 50 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity/Adverse Events from treatment</measure>
    <time_frame>Day 1 of each cycle of treatment, and 30 days post end of treatment</time_frame>
    <description>The investigators will compare the toxicity profiles of the two arms of therapy to determine if the docetaxel + suramin has a more favorable toxicity profile than docetaxel alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of peripheral blood lymphocytes for DNA damage-induced checkpoint control.</measure>
    <time_frame>Baseline</time_frame>
    <description>The investigators hypothesize that suramin in combination with docetaxel improves response rates and survival by preventing the cancer cells to enter M phase of the cell cycle.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Carcinoma, Non Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel plus Suramin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>IV over 60 minutes, 75 mg/m2</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suramin</intervention_name>
    <description>IV over 30 minutes</description>
    <arm_group_label>Docetaxel plus Suramin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>IV over 60 minutes. 56 mg/m2</description>
    <arm_group_label>Docetaxel plus Suramin</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven diagnosis of non-small cell lung cancer

          -  Documented disease progression after first-line chemotherapy for non-small cell lung
             cancer

          -  Stable and treated CNS metastasis is allowed

          -  Radiation must be completed at least 2 weeks prior to starting protocol treatment

          -  Major surgery must be completed at least 4 weeks prior to starting protocol treatment

          -  ECOG performance status 0-2

          -  Sexually active patients must use adequate contraception

          -  Adequate bone marrow function

          -  Adequate renal function

          -  Adequate liver function

        Exclusion Criteria:

          -  Severe hypersensitivity reaction to docetaxel

          -  Pre-existing grade 3 or 4 neuropathy

          -  Women who are pregnant or breastfeeding

          -  Uncontrolled intercurrent illness

          -  Receipt of 3 or more prior chemotherapy regimens
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne M Traynor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Santana-Davila, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2012</study_first_submitted>
  <study_first_submitted_qc>August 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2012</study_first_posted>
  <disposition_first_submitted>June 29, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 5, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 2, 2016</disposition_first_posted>
  <last_update_submitted>August 5, 2016</last_update_submitted>
  <last_update_submitted_qc>August 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma, non small cell lung</keyword>
  <keyword>Second line</keyword>
  <keyword>Third line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Suramin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

